5:30pm–7:00pm No-host meet & greet
8:00pm Announcements and technical presentation
Ph.D., Chemistry, University of California, Berkeley, 20016 Staff Scientist, Chemical Sciences Division, and
Deputy Director, Institute for Resilient Communities,
Lawrence Berkeley National Laboratory
Dr. Abergel's research program is dedicated to understanding the coordination chemistry of heavy and radioactive elements to develop new nuclear decontamination strategies, new therapeutics for radioimmunotherapy, or new light harvesting materials. She leads a large collaborative effort on the development of new drug products for the treatment of populations contaminated with radionuclides. One of these products was granted an Investigational New Drug status from the U.S. Food and Drug Administration in 2014. In addition, she has been actively involved in the new Lawrence Berkeley National Laboratory Initiative for Resilient Communities, the radiological component of which was sparked by the aftermath of the 2011 Fukushima Daiichi accident.
Dr. Abergel was raised in France and graduated from the École Normale Supérieure of Paris in 2002. She conducted her graduate studies in inorganic chemistry at UC Berkeley, under the supervision of Professor Kenneth Raymond. Her doctoral work focused on the synthesis and characterization of siderophore analogs to probe microbial iron transport systems and design new iron chelating agents. As a joint postdoctoral researcher between the UC Berkeley Chemistry Department and the group of Professor Roland Strong at the Fred Hutchinson Cancer Research Center, she investigated the bacteriostatic function of the innate immune protein siderocalin in binding siderophores from pathogenic microorganisms such as Bacillus anthracis, for the development of new antibiotics. Dr. Abergel joined Berkeley Lab in 2009, where she currently serves as the chair of the Radioactive Drug Research Committee and is an associate editor for the International Journal of Radiation Biology and a corresponding member (USA) for Radioprotection. In 2014, Dr. Abergel received an Early Career Award from the U.S. Department of Energy and was selected as an Innovator under 35 – France by the MIT Technology Review. She is also the recipient of a Junior Faculty NCRP award (2013) from the Radiation Research Society, and a Young Investigator Research Fellowship (2010) from the Cooley’s Anemia Foundation.
Development of New Therapeutics for Radionuclide Decorporation: From Discovery to Product Availability
Abstract: The threat of a major radiological contamination presents a danger of not only large-scale external radiation exposure of the population but also internal contamination with radionuclides. While major components of such contamination are likely to be actinides and lanthanide fission products, current therapies for the treatment of f-element internalization are still limited. Over the past three decades, the Lawrence Berkeley National Laboratory has dedicated a research program to the discovery of oral therapeutics for actinide decorporation, leading to the emergence of the active pharmaceutical ingredient 3,4,3-LI(1,2-HOPO) as an exceptional candidate for actinide sequestration.
This chelator is currently undergoing advanced development for the treatment of individuals with known or suspected internal contamination with actinides such as plutonium (Pu), americium (Am), curium (Cm), uranium (U) or neptunium (Np) to increase the rates of elimination of these radionuclides. Following the submission of an Investigational New Drug application, the U.S. Food and Drug Administration approved the first clinical study for the decorporation agent 3,4,3-LI(1,2-HOPO) in August 2014. The scientific and regulatory work undertaken for the successful development of such new decorporation therapeutic option will be presented.
The dinner menu features a choice of entrée and dessert:
This meeting will be at Trader Vic's in Emeryville.
Trader Vic's Emeryville
9 Anchor Dr.
Emeryville, CA 94608
Phone: (510) 653-3400
Valet parking is free in the restaurant parking lot, and there is additional street parking nearby.